Effectiveness and risk with LapDap A classic dilemma Personal views: I Ralph Edwards.

Slides:



Advertisements
Similar presentations
MICS3 Data Analysis and Report Writing
Advertisements

The management of adverse drug reactions I Ralph Edwards
Artesunate Rectal Capsules For the initial management of acute malaria in patients who cannot take medication by mouth and for whom parenteral treatment.
Tuberculosis in Children: Prevention Module 10C - March 2010.
THE INAPPROPRIATE SALE OF MEDICATION FOR PEDIATRIC USE IN SIEM REAP PROVINCE, KINGDOM OF CAMBODIA AUTHORS: Sothearith Tiv Ph., Rathi Guhadasan MBBS MRCP.
Modernization of Canada’s Yellow Fever Vaccination Program
1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.
Caroline Lynch & Jim Tulloch June 2014 Synthesis of current evidence on the multiple causes of malaria drug resistance.
Pneumonia Sapna Bamrah, MD CDC
Nonprescription Simvastatin in the United Kingdom Michael L. Koenig, Ph.D. Interdisciplinary Scientist Division of Over-the-Counter Drug Products Center.
Antimicrobial resistance “One health fits all”
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
World Health Organization
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
Choice of antimalarial drugs Malaria Medicines & Supplies Services RBM Partnership Secretariat.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
Moving forward in the diagnosis of infectious diseases in developing countries: a focus on malaria Forum organized by Fondation Mérieux & the Roll Back.
FUTURE RESEARCH ON MALARIA: Towards a malaria-free country Emiliana Tjitra National Institute of Health Research and Development Jakarta, 30 April 2015.
NATIONAL DRUG AUTHORITY - UGANDA | Slide 1 of February 2010, Geneva, Switzerland How the African NMRAs are benefiting from the WHO medicines prequalification.
9/11 “The Malaria epidemic is like loading up seven Boeing 747 airplanes each day then deliberately crashing them into Mt Kilamanjaro” Chairman Malaria.
The South African Malaria Initiative A Case Study E Jane Morris Bridging the Gap in Global Health Innovation - from Needs to.
WHO Traditional Medicine Strategy and Guidelines Dr Arvind Mathur MD, DHA, DNB Cluster Coordinator Family & Community Health WHO-India World Health Organisation.
Unlicensed Medicines in Paediatrics Is there a problem ? Scottish Neonatal and Paediatric Pharmacist Group National Paediatric Pre- Registration Pharmacist.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Methemoglobinemia Related to Local Anesthetics: A Summary of 242 Episodes Diana Lee, D.O. PGY-1 Journal Club October 21, 2009.
1 Towards the future: medicines and the elimination of malaria Defeating Malaria Together Timothy N.C. Wells PhD ScD Chief Scientific Officer MMV.
Paracetamol Nimesulide. “ Humanity has but three great enemies; Fever, Famine and War. Of these by far the most terrible, is fever.” ( Sir William Osler.
1 |1 | Key problems Neglected Tropical Diseases Hidden and silent : Key problems Complacency, lack of information and commitment Complacency, lack of information.
T e c h n i c a l S e m i n a r s Malaria Overview Overview Case DefinitionCase Definition Kills Quickly Malaria Risk HighHigh Low How to Assess ClassificationLowHow.
NEVIRAPINE THE CONCERNS REGISTRAR OF MEDICINES 15 AUGUST 2002.
MCA Risk:benefit analysis of Kava-kava Update as at 12 Feb 2002.
Pharmacovigilance of antimalarial drugs in Uganda Hasifa Bukirwa Uganda Malaria Surveillance Project Funded by: CDC/PMI and EDCTP.
Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.
From the Lab to Market Unit 3.04 Understanding Biotechnology research & Development.
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
Biomedical Research.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Quality Control Approaches for Essential Medicines “Good Intentions – Bad Drugs” The World Bank March 10, 2005.
CTD, Safety Tanja Braakman Genzyme Europe BV Pharmacovigilance Department.
PharmacogeneticsPharmacogenetics Dr, P Derakhshandeh, PhD Dr, P Derakhshandeh, PhD.
Personal Protection Against Malaria avoidance of exposure to mosquitoes at their peak feeding times (usually dusk and dawn) and throughout the night use.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 7 Over-the-Counter Drugs and Herbal and Dietary.
The Economic Rationale for the ACT Subsidy Kenneth J. Arrow Amsterdam 18 January 2007.
Issues in malaria diagnosis and treatment May 31, 2007 Jacek Skarbinski, MD Malaria Branch Centers for Disease Control and Prevention.
21/4/2008 Evaluation of control measures 1. 21/4/2008 Evaluation of control measures 2 Family and Community Medicine Department.
GLUCOSE-6-PHOSPATE DEHYDROGENASE DEFICIENCY GENETICS PRESENTATION BY GROUP A2(MD2) WINDSOR UNIVERSITY SCHOOL OF MEDICINE. IVEREN,FOLA,FLOURISH, ALLISON,
Benefit and harm: Effectiveness and risk Key concepts in therapeutics Key issues in communication I Ralph Edwards Marie Lindquist With acknowledgements.
RELEVANCERELEVANCE Is the objective of the article on harm similar to your clinical dilemma? Yes, the article’s objective is similar to the clinical dilemma.
Dr Mary Couper Quality Assurance and Safety of Medicines WHO
Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.
European Patients’ Academy on Therapeutic Innovation Special Populations.
Pharmaceutical Working Group Working Group on Pharmaceuticals Key Points for Advocacy and Action.
Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.
Date Insert on Master Slide Slide 1 Regulatory Framework within which patients can have safe and more convenient access to medicines Royal College of Physicians.
Viagra (sildenafil citrate): Extensive Clinical and Post-Marketing Experience Michael Sweeney, MD Senior Medical Director Pfizer Inc.
Sayed Ali Mus POST GRADUATES-BATCH 6 FACULTY OF MEDICAL LABORATORY SCIENCES PARASITOLOGY DEPARTMENT ALNEELIN UNIVERSITY March 2015 Symposium on: Advances.
Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase–deficient children receiving dapsone by Allan Pamba, Naomi D. Richardson,
Clinical Trials.
Pharmacology Science that studies interactions of drugs with organism on different levels (subcellular, cellular, organ, systemic) Studies: - relationship.
Introduction to general pharmacology.
Efficacy and Safety of Medicines
Copyright © 2016 by Mosby, an imprint of Elsevier Inc.
1. Structure and training objectives for this course & key references
Change in malaria treatment policy: A study of its immediate effects on hospital malaria drug management, utilization of hospital facilities and prescription.
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
Assessment and Management of Acute Pain: A Focus on the Role of Opioids and Multimodal Treatment Approaches.
Quality Problems with Antimalarials
Effectiveness and risk with LapDap
PROSES TERAPI DAN PERMASALAHANNYA
Anthony D Harries Ministry of Health, Malawi
Presentation transcript:

Effectiveness and risk with LapDap A classic dilemma Personal views: I Ralph Edwards

What is LapDap Two very old drugs, combined for a new indication: Malaria –Chlorproguanil An little used anti-malarial –Dapsone An anti-leprotic and immunomodulator

Mystic Herbal balm ?

Is the combination effective in malaria? Yes, in studies of nearly 3000 African subjects (nearly all children) published in the Lancet and submitted to the UK MHRA, it is very effective –Also in sulfadoxine-pyrimethamine resistance In Asia there is considerable resistance developed The time window for effective use in Africa may be limited It is also cheap: around the same price as chloroquine

Is it safe? Considerable inter-individual variability in plasma levels of both drugs –? Genetic polymorphisms –No PK studies in elderly or diseased –Limited previous experience in children –Dapsone dose about 2x its use in leprosy, and close to toxic dose –Limited experience with chlorproguanil, but no major problems

But….. Dapsone causes: –Variably severe haemolysis in people with G6PD deficiency >20% of Africans have the deficiency to some extent They will not know they have it unless tested –Methaemaglobinaemia, with reduced oxygen carryng capacity Malaria also causes haemolysis!!

Registration of LapDap First registered in UK, now in <20 African countries –UK conditions are: Prescription only Contraindicated in G6PD There is no serious restriction on availability imposed in Africa How will patients know they are G6PD deficient anyway About 50% of patients who treat themselves for malaria do not have the disease

”Pull out, Bettyl Pull out...You’ve hit on artery”

Review of Safety of Chlorproguanil/Dapsone WHO Technical Consultation Geneva, 1-2July, 2004 Publ. March 2005 The executive summary only

Chlorproguanil/Dapsone Should be used only if the diagnosis of malaria is confirmed. Should only be used after anaemia have been excluded by a reliable clinical or laboratory test and G6PD deficiency by a reliable laboratory test. – The diagnosis of methaemoglobinemia is less important

Chlorproguanil/Dapsone In areas where G6PD deficiency is prevalent, it is important before using CPG- DDS to know the level of anaemia and the G6PD status of the patient. If appropriate tests are not possible, an alternative antimalarial medicine should be used. If there is no suitable alternative, CPG-DDS should be used taking into account all the risks associated with this medicine.

Chlorproguanil/Dapsone These recommendations are to be reconsidered when more data becomes available from pharmacovigilance and active post-marketing surveillance. – Safety studies have yet to be done!

Implications What is its safety on repeated use? Is this a good combination with artemesinin derivatives? –For: Cheap and effective –Against: Safety, as we assess it now